BD Diagnostics has announced the US launch of the BD Max benchtop molecular system, designed to be used for in vitro diagnostic assays, user-defined protocols and life-science research applications.
The BD Max system gives clinical laboratory professionals the ability to help their institutions respond to emerging threats, such as new strains of deadly drug-resistant bacteria or respiratory illnesses.
Earlier this month, BD announced a collaboration with Diagenode to develop seven initial assays for the BD Max system.
These assays will include a panel for diagnosing respiratory infections, two panels for diagnosing virus- and parasite-based gastrointestinal infections and a panel for differentially diagnosing meningitis.
The BD Max system's open capability, full automation, standardised workflow and planned content-rich menu will enable laboratories to consolidate and standardise a range of molecular tests to build programmes that meet their current and future clinical needs.
